Estabrook Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Estabrook Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$193K	Hold	250	–	–	0.03%	120
2025 Q4	$193K	Hold	250	–	–	0.03%	120
2025 Q3	$141K	Hold	250	–	–	0.02%	132
2025 Q2	$131K	Hold	250	–	–	0.02%	137
2025 Q1	$159K	Hold	250	–	–	0.03%	124
2024 Q4	$178K	Hold	250	–	–	0.03%	124
2024 Q3	$263K	Hold	250	–	–	0.04%	119
2024 Q2	$263K	Hold	250	–	–	0.04%	120
2024 Q1	$241K	Hold	250	–	–	0.04%	125
2023 Q4	$220K	Hold	250	–	–	0.04%	126
2023 Q3	$206K	Sell	250 -30	-11%	-$23.6K	0.04%	129
2023 Q2	$201K	Hold	280	–	–	0.03%	133
2023 Q1	$230K	Hold	280	–	–	0.04%	130
2022 Q4	$202K	Hold	280	–	–	0.03%	135
2022 Q3	$193K	Hold	280	–	–	0.04%	134
2022 Q2	$166K	Hold	280	–	–	0.03%	141
2022 Q1	$196K	Hold	280	–	–	0.03%	138
2021 Q4	$177K	Buy	280 +30	+12%	+$18.4K	0.03%	148
2021 Q3	$151K	Hold	250	–	–	0.02%	142
2021 Q2	$140K	Hold	250	–	–	0.02%	150
2021 Q1	$118K	Hold	250	–	–	0.02%	160
2020 Q4	$121K	Buy	+250	New	+$135K	0.02%	153

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Estabrook Capital Management's REGN Position: Q1 2026 in Review

Estabrook Capital Management held its Regeneron Pharmaceuticals (REGN) position steady in Q1 2026 at 250 shares worth $193K. The position accounts for 0.03% of the portfolio, ranked #120.

Estabrook Capital Management first reported a position in REGN in Q4 2020 and has held it in 22 quarters since. The position peaked at $263K in Q3 2024. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Estabrook Capital Management held 250 shares of Regeneron Pharmaceuticals worth $193K as of Q1 2026.
Estabrook Capital Management left its Regeneron Pharmaceuticals share count unchanged in Q1 2026.
Regeneron Pharmaceuticals made up 0.03% of Estabrook Capital Management's portfolio in Q1 2026, its #120 holding.
Estabrook Capital Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and has held it in 22 quarters since.
Estabrook Capital Management's Regeneron Pharmaceuticals position peaked at $263K in Q3 2024.
1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Estabrook Capital Management's 13F filing for Q1 2026, filed 14 May 2026.